<DOC>
	<DOCNO>NCT00593957</DOCNO>
	<brief_summary>Increased brain glutamate N-methyl-D-aspartate ( NMDA ) receptor find brain young Rett syndrome ( RTT ) patient cause toxic damage neuron ( brain 's nerve cell ) , contribute EEG spike . Dextromethorphan ( DM ) act block NMDA/glutamate receptor . This study do determine DM prevent harmful over-stimulation neuron thereby reduce EEG spike activity . Treatment DM consist one 3 different dos ( 0.25 mg/kg per day ; 2.5 mg/kg/day ; 5mg/kg/day ) , aim find dose help improve EEG abnormality , behavior , cognition , reduce seizure , well improve breathe abnormality , motor capability , bone density , GI dysfunction . The study include 90 female male RTT , 2 years-14.99 year age , mutation methyl CpG binding protein 2 ( MECP2 ) gene , spike EEG , without clinical seizure .</brief_summary>
	<brief_title>Trial Dextromethorphan Rett Syndrome</brief_title>
	<detailed_description>Patients meet eligibility criterion ( mutation +ve EEG spike ) , admit Pediatric Clinical Research Unit Johns Hopkins Hospital pharmacokinetics DM determine establish rapid metabolizers drug . The baseline study initial admission include neurological , neuropsychology , EEG , gastroenterology , Occupational Physical therapy evaluation . If subject rapid metabolizer randomize one three drug dos . They contact telephone , weekly first month , monthly thereafter . They examine neurologist 2 weeks,1 month , 3 month drug trial . At visit also monitor change complete blood count ( CBC ) , electrolytes , EKG . At end 6 month drug trial patient readmitted Johns Hopkins Hospital baseline study repeat . Cost travel , hospitalization interim test free participant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>1. classic atypical RTT proven mutation MeCP2 gene ; 2. document EEG evidence spike activity may may clinical seizure ; 3. subject must 2years 14.99 year age . 1. without establish mutation MeCP2 gene ; 2. EEG evidence spike activity ; 3. mutation MeCP2 gene brain resection surgical intervention ; example , tumor , hydrocephalus , severe head trauma ; , associate severe medical illness vasculopathies , malignancy , diabetes , thyroid dysfunction , etc ; 4. medication could interact DM , e.g . monoamine oxidase ( MAO ) inhibitor , selective serotonin reuptake inhibitor ( SSRI ) , sibutramine etc . avoid serotonin syndrome ; quinidine drug metabolize Cytochrome P450 ( CYP450 ) isoform cytochrome P450 2D6 ( CYP2D6 ) ( e.g . amiodarone , haloperidol , propafenone , thioridazine ) ; 5. proven intermediate slow metabolizers DM ; 6. report adverse reaction DM ; 7. whose pregnancy test positive ; , 8. show poor compliance aspect study ; 9. foster child</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Rett Syndrome</keyword>
	<keyword>Dextromethorphan</keyword>
</DOC>